DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)

Prior treatment

• Patients who received a combination of DES and DCB in the same vessel

Other illness

• Patients who meet at least one of the following conditions are excluded:
• Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery.
• Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion.
• Patients with symptomatic congestive heart failure.
• Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids).
• Patients with heart transplant.

Lab values

• Patients with anemia (Hb \<12 g/dL in men and \<10 g/dL in women).

Age

• Patients, women of childbearing age with a positive pregnancy test.

Other

• Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG).
• Patients with glomerular filtration rate \<30 ml/min/ 1.73 m2
• Patients with body mass index \>35 (may affect the evaluation qualitative diameter of the coronary artery).
• Pregnant female patients.
• Patients included in other clinical trials with active follow-up.

• Patients who meet all of the following conditions are included.
• Patients aged ≥ 18 years and;
• Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and;
• Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and;
• Patients who have been informed of the characteristics of the study and have provided their written informed consent.